Our study also demonstrates that targeting ATG4B leads to SESN3 enhancement to inhibit both mTOR/S6K signaling and ATG4B-mediated autophagy, which hampers T-ALL progression and possibly presents a new option for the disease treatment. Here, SESN3 is linked to acute lymphoblastic leukemia.